{"transactions":[{"id":4628427,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":28933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":482478,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":28933},"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628426,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2600,"price":93.46,"value":242996.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2845,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628425,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":92.7,"value":194670.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":5445,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628424,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":7228,"price":91.35,"value":660277.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":7545,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628423,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":16605,"price":90.35,"value":1500261.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":14773,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628422,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":89.24,"value":35696.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":31378,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628421,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":28933,"price":14.5,"value":419528.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."}],"balance_after":31778,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4046,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":511411,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4045,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":27999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":511811,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":27999},"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4044,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":400,"price":90,"value":36000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":2845,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4043,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":14.5,"value":5800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":3245,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4042,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":89.38,"value":35752.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":2845,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4041,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":6206,"price":88.17,"value":547183.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.73 to $88.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":3245,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4040,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":16548,"price":87.2,"value":1442985.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.71 to $87.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":9451,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4039,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":4845,"price":86.4,"value":418608.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.71 to $86.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":25999,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4038,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":27999,"price":14.5,"value":405985.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":30844,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":939898,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-14T02:25:34.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":140000,"derivative":{"exercise_price":30.61,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001636282-26-000001","document":"wk-form4_1768357531.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000001/wk-form4_1768357531.xml","form_type":"4"}},{"id":1299661,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-17T21:34:06.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":95500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":95500,"derivative":{"exercise_price":21.66,"expiration_date":"2035-01-15","underlying":"Common Stock","underlying_shares":95500},"source":{"system":"sec-edgar","filing":"0001636282-25-000007","document":"wk-form4_1737149638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000007/wk-form4_1737149638.xml","form_type":"4"}},{"id":1660696,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-03T01:23:54.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 63,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":63000,"derivative":{"exercise_price":25.86,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0000950170-24-010896","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024010896/ownership.xml","form_type":"4"}},{"id":1788733,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-05T20:15:57.000Z","date":"2023-09-01","kind":"grant","planned":false,"acquired":true,"shares":13495255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 13,495,255 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":13495255,"derivative":{"exercise_price":0.58,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":13495255},"source":{"system":"sec-edgar","filing":"0000950170-23-046396","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023046396/ownership.xml","form_type":"4"}},{"id":1912322,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:00:20.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":8.93,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-23-013903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013903/ownership.xml","form_type":"4"}},{"id":1912321,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:00:20.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":145000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.39,"underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001493152-23-013903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013903/ownership.xml","form_type":"4"}},{"id":1912320,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:00:20.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":139500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.8,"underlying":"Common Stock","underlying_shares":139500},"source":{"system":"sec-edgar","filing":"0001493152-23-013903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013903/ownership.xml","form_type":"4"}},{"id":1912319,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-27T18:00:20.000Z","date":"2023-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. (\"Parent\"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of April 27, 2023 (the \"Effective Time\"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":11.23,"underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001493152-23-013903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013903/ownership.xml","form_type":"4"}},{"id":2056520,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-11T21:11:37.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 10, 2024) and the remaining 75% will vest and become exercisable monthly over 36 months such that the\noptions are fully vested and exercisable on the four-year anniversary of the grant date (January 10, 2027)."}],"balance_after":200000,"derivative":{"exercise_price":8.93,"expiration_date":"2033-01-10","underlying":"Common Stock, par value $0.0001","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-23-001209","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223001209/ownership.xml","form_type":"4"}},{"id":2105310,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-23T21:28:09.000Z","date":"2022-11-22","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 4 filed on August 3, 2020, on August 3, 2020 the Reporting Person was granted a stock option for 300,000 shares of Common Stock, 120,000 of which option shares vest in four equal annual installments commencing on August 3, 2021 and 180,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 90,000 of the 180,000 performance option shares on November 22, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 90,000 option shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the 120,000 time-based option shares referred to in footnote (1) plus the 30,000 vested performance option shares which vested August 3, 2021 plus 60,000 vested performance option shares which vested March 22, 2022 plus the 90,000 vested performance option shares referred to in footnote (1)."}],"balance_after":300000,"derivative":{"exercise_price":11.23,"exercise_date":"2022-11-22","expiration_date":"2030-08-03","underlying":"Common Stock, par value $0.0001","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001493152-22-033640","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315222033640/ownership.xml","form_type":"4"}},{"id":2318916,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-24T18:01:44.000Z","date":"2022-03-22","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 4 filed on August 3, 2020, on August 3, 2020 the Reporting Person was granted a stock option for 300,000 shares of Common Stock, 120,000 of which option shares vest in four equal annual installments commencing on August 3, 2021 and 180,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 60,000 of the 180,000 performance option shares on March 22, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 60,000 option shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the 120,000 time-based option shares referred to in footnote (1) plus the 30,000 vested performance option shares which vested August 3, 2021 plus the 60,000 vested performance options shares referred to in footnote (1)."}],"balance_after":210000,"derivative":{"exercise_price":11.23,"exercise_date":"2022-03-22","expiration_date":"2030-08-03","underlying":"Common Stock, par value $0.0001","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001493152-22-007705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315222007705/ownership.xml","form_type":"4"}},{"id":2430630,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-20T17:22:57.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 18, 2023) and the remaining 75% will vest and become exercisable monthly over 36 months such that the\noptions are fully vested and exercisable on the four-year anniversary of the grant date (January 18, 2026)."}],"balance_after":145000,"derivative":{"exercise_price":4.39,"expiration_date":"2032-01-18","underlying":"Common Stock, par value $0.0001","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001493152-22-001759","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315222001759/ownership.xml","form_type":"4"}},{"id":2613051,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-05T16:07:02.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 4 filed on August 3, 2020, on August 3, 2020 the Reporting Person was granted a stock option for 300,000 shares of Common Stock, 120,000 of which option shares vest in four equal annual installments commencing on August 3, 2021 and 180,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 30,000 of the 180,000 performance option shares on August 3, 2021 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 30,000 option shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the 120,000 time-based option shares referred to in footnote (1) plus the 30,000 vested performance option shares referred to in footnote (1). Excludes 150,000 of the previously reported 300,000 option shares referred to in footnote (1) that are performance option shares that remain subject to vesting upon completion of certain performance milestones."}],"balance_after":150000,"derivative":{"exercise_price":11.23,"exercise_date":"2021-08-03","expiration_date":"2030-08-03","underlying":"Common Stock, par value $0.0001","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-21-018719","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315221018719/ownership.xml","form_type":"4"}},{"id":2712403,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-05-14T19:41:17.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":139500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"69,750 of the options granted will vest as follows: 25% will vest and become exercisable on May 12, 2022 and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on May 12, 2025. The remaining 69,750 of the options granted will vest and become exercisable, if at all, in three equal installments of 23,250 options, with each such installment triggered upon the achievement of one of three separate corporate performance milestones prior to or during the year 2024."}],"balance_after":139500,"derivative":{"exercise_price":6.8,"expiration_date":"2031-05-12","underlying":"Common Stock, par value $0.0001","underlying_shares":139500},"source":{"system":"sec-edgar","filing":"0001493152-21-011581","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315221011581/ownership.xml","form_type":"4"}},{"id":3071416,"issuer":{"id":12101,"kind":"organization","name":"Provention Bio, Inc.","symbol":"PRVB"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-03T17:35:36.000Z","date":"2020-08-03","kind":"grant","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. 120,000 option shares vest in four equal annual installments commencing on August 3, 2021; the remaining 180,000 option shares vest upon completion of certain performance milestones."}],"balance_after":300000,"derivative":{"exercise_price":11.23,"expiration_date":"2030-08-03","underlying":"Common Stock, par value $0.0001","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001493152-20-014505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315220014505/ownership.xml","form_type":"4"}},{"id":3333685,"issuer":{"id":116059,"kind":"organization","name":"Axcella Health Inc.","symbol":"AXLA"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, SVP Legal"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-20T20:03:51.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on December 18, 2020, with the remainder to vest in 12 equal quarterly installments thereafter."}],"balance_after":35000,"derivative":{"exercise_price":3.4,"expiration_date":"2029-12-18","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-19-075209","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633070/000110465919075209/a4.xml","form_type":"4"}}]}